Balyasny Asset Management
ADMA icon

Balyasny Asset Management’s ADMA Biologics ADMA Stock Holding History

Balyasny Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,018,239
Closed -$14.9M – 3038
2025
Q3 		$14.9M Buy
1,018,239
+46,825
+5% +$803K 0.02% 855
2025
Q2 		$17.7M Buy
971,414
+589,707
+154% +$12M 0.03% 715
2025
Q1 		$7.57M Buy
+381,707
New +$6.6M 0.01% 1066
2024
Q4 		– Sell
-446,388
Closed -$8.92M – 2677
2024
Q3 		$8.92M Sell
446,388
-1,048,351
-70% -$16.3M 0.01% 1012
2024
Q2 		$16.7M Buy
1,494,739
+1,435,397
+2,419% +$12M 0.03% 672
2024
Q1 		$392K Buy
59,342
+27,131
+84% +$148K ﹤0.01% 2153
2023
Q4 		$146K Buy
+32,211
New +$119K ﹤0.01% 2353
2022
Q2 		– Sell
-143,115
Closed -$262K – 2699
2022
Q1 		$262K Buy
+143,115
New +$223K ﹤0.01% 1964

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Balyasny Asset Management's ADMA Position: Q4 2025 in Review

Balyasny Asset Management sold out of ADMA Biologics (ADMA) in Q4 2025, closing a stake of 1,018,239 shares — an estimated $14.9M sold.

Balyasny Asset Management first reported a position in ADMA in Q1 2022 and held it in 8 quarters. The position peaked at $17.7M in Q2 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q4 2025.

  • Balyasny Asset Management reported no remaining ADMA Biologics position as of Q4 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 1,018,239 ADMA Biologics shares in Q4 2025, an estimated $14.9M.
  • Balyasny Asset Management first reported a position in ADMA Biologics in Q1 2022 and held it in 8 quarters.
  • Balyasny Asset Management's ADMA Biologics position peaked at $17.7M in Q2 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.